Transaction Report:
(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)
1st Editorial Decision 08 November 2009
Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three expert reviewers, whose comments are copied below. As you will see, these reviewers consider your identification of MAGED1 as a nuclear receptor-associated circadian clock modulator interesting in principle and therefore potentially suited for publication in The EMBO Journal. Nevertheless, they also raise a number of important concerns that we feel would need to be satisfactorily addressed and clarified before publication in these pages may be warranted. One recurring concern in this respect is the question of how MAGED1 may affect RORalpha-controlled gene expression on the molecular level, which would need to be substantiated by additional experimental evidence.
Should you be able to adequately address this as well as the other major points of the referees, we should be happy to consider a revised manuscript for publication. I would therefore like to invite you to prepare such a revised version, taking into account also the various referee comments on editorial issues -such as better description of protocols and resources, accurate and complete referencing, and possibly also straightening of the title to something like 'Interaction of MAGED1 with nuclear receptors affects circadian clock function'.
Please let me add that it is EMBO Journal policy to allow a single round of major revision only, and that it is therefore important to adequately answer to all the points raised at this stage if you wish the manuscript ultimately to be accepted. When preparing your letter of response, please also bear in mind that this answer will form part of the Review Process File, and will therefore be available
The authors provide here evidence for a role of MAGED1 (Melanoma Antigen Family D1) within the mammalian circadian network. This protein is different from other MAGE proteins in that it is expressed ubiquitously. Although this protein was shown to be involved in signaling pathways (e. g. it interacts with p75NTR) or to modulate the activity of homeodomain-containing transcription factors, a general function for this protein in other tissues was not described yet. From the characterization of their knock out mice, they conclude that MAGED1 is a co-activator of ROR alpha-dependent transcription and that this may explain the observed phenotypes. This point, however, has to be reconsidered.
Major point:
If the conjecture is true that MAGED1 acts only as a co-activator of ROR alpha, then Maged1-knock out mice should display similar or less severe phenotypes than ROR alpha-deficient ("staggerer") mice. In terms of the rapid adaptation of Maged1 KO mice this may be correct. These mice behave like +/staggerer heterozygous mice indicating that ROR alpha doesn't have the full transcription regulatory potential (Sato et al., 2004) . At the same token, the free-running periodlengths of Maged1 KO and homozygous staggerer mice are roughly comparable. However, in the liver there is barely an impact of the lack of ROR alpha on the rhythmic expression of the Bmal1 gene (Sato et al., 2004) in sharp contrast to the situation in the Maged1 KO mice. This is clearly a weak point of the manuscript. The action of MAGED1 on Bmal1 in the liver is clearly not restricted to the interaction with ROR alpha. Therefore, the entire argumentation regarding the importance of this interaction and the "direct" effects of MAGED1 on the circadian oscillator becomes quite soft and consequently the function of MAGED1 remains elusive. There should be more convincing experiments included to round up the story (e. g. chromatin immunoprecipitation of MAGED1 and ROR alpha at a target gene, co-immunoprecipitation of MAGED1 with other nuclear receptors involved in the regulation of the Bmal1, Rev-Erb alpha and E4BP4 genes in the liver, etc.)
Other points: 1) Introduction: The introduction (especially the first paragraph) is barely comprehensible for experts in the field let alone for a general readership. There should be clear definitions of "circadian clocks" and "circadian robustness". In addition, some references are not properly cited (page 4: Stokkan et al, 2001 was an important paper regarding the entrainment of peripheral oscillators by an inverted food regimen; the expression "sleep-wake", for which it was cited, shows up only once in the reference list.)
2) Citation of the reference should be better in accordance with the content of the paper. There are other examples in this manuscript, e. g. in the first paragraph of the discussion. Feillet et al., 2006 analyze the impact of the PER2 protein on the food anticipatory activity, let alone provides evidence for survival advantages in competitive environments.
Referee #3 (Remarks to the Author):
Comments This is an interesting manuscript where the authors described the phenotype of the MAGED1 knock out mice and investigated its role in the clock system. Main findings of the paper are following.
1) Maged1 knock-out mice showed shorter period of behavioral rhythm under DD conditions than that of wild type littermates.
2) In Maged1 k.o. mice, Bmal1 and E4bp4 expression rhythm amplitude was attenuated whereas RevErba expression rhythm amplitude was enhanced.
3) MAGED1 directly binds to RORa and controls RORa transcriptional activity.
This paper well described the observation of the newly identified knock-out model mice and introduce the possible new member of the clock components to the researchers in chronobiology field. I think this paper is worth for publication in the EMBO J after authors revise their manuscript in the following points.
Major Points. Minor Points. 1. In some case, they used the materials which they did not mention in the materials and methods section. For example, they used Per1::Luciferase rat fibroblast which they do not mention in material and methods. They also did not mention the detail protocol of tissue sampling. In Fig.3A , they explained liver clock genes expression level but they did not mention when they collect tissues and even not mention whether they collect tissues under DD or LD. I can understand sampling was performed under DD because they used CT but it is not kind enough for the readers who are not familiar with the chronobiological field. Authors should explain more carefully about the method, or cite precise literatures.
2. Although they mentioned about the behavioral screening project aiming to identify mice which show circadian clock abnormality in Introduction, they did not mention the scale of the screening or resource of the mice stock they used. I recommend authors to mention more detail about screening they performed or cite precise literature about the screening project to give enough information to readers.
3. In Fig.3C , they showed clock proteins data of lung and also mentioned about those of liver in the text without showing data. I recommend authors to show liver data as most of the RNA expression analysis was performed using liver samples. 5. I was confused when I read the description about the MEFs (page 7). They crossed "Maged1+/-to the mPER2::LUC knock-in reporter mouse". Does this mean they crossed FEMALE Maged1+/-to MALE mPer2::Luc k.i.? They also described that they observed "first cycle of mPER2::LUC in Maged1 -/-/mPER2::LUC MEF cells". Does this mean that they used homozygote female knockout mouse embryo to make MEFs? Or Alternatively, did they use male Maged1 KO mouse embryo to make MEFs? Please clarify these.
6. At page12, they mentioned that they used "3T3 NIH cells" (line6) and "NIH3T3 cells" (line13). Are these the same cell line? If so, please use "NIH3T3". At page12, they did "co-transfection of E4bp4 and Rora expression plasmids" and measured E4bp4 promoter activity, but from Fig.6 , "cotransfection of Maged1 and Rora" may be correct.
More Minor points. 1. According to authors, as Maged1 gene is located in chromosome X, no homozygote Maged1 knock out male mice exist and then authors limited their experiments in only male mice for behavioral studies because they could not obtain enough number of WILD type female littermates. This sounds a little bit strange and may not be a sufficient reason to justify that their experiments are limited only to male. The readers may want to know whether there are any differences between male and female knock-out mice.
2. They argued some clock gene circadian rhythm showed delay (Clock) and others (Per2, Cry2) show advances in knock out mice liver (Fig.3A) . Ideally speaking, the authors should observe at least two cycles of genes expression for confirmation.
1st Revision -authors' response 25 January 2010
Below are detailed point-to-point responses to the referees' comments:
Referee #1 (Remarks to the Author):
Wang et al. found MAGED1 (Melanoma Antigen Family D1)-deficient mice a shorten period. They describe MAGED1 binds to RORa and plays a role on core clock genes including Bmal1 through RORE, and define it as a circadian regulator.
The analyses are systematic and seem to include full study, however, the reviewer raises several questions and comments before publication. Figure 2C , although the authors describe the numbers examined are 9 and 8 in the text. Whole data should be included.
Only 2 traces for each were shown in
We have followed the suggestion to include all data in two panels of Figure 2C . This avoids showing more waveforms than can be discerned in one figure. As suggested by Referee 3, in point 2, we also added adrenal and testis data to Figure 2C . Both tissues show a shortened circadian period that is consistent with the cellular observations. The manuscript was revised on Page 7 Line 20-24, Page 8 Line 1-4 and Figure 2 legends, Page 27 Line 15-17. The referee brings up an important point regarding the data on bidirectional effects on circadian expression by MAGED1. We are in complete agreement with the referee that Dbp and Npas2 should be included to clarify our conclusion. As shown in the revised manuscript Page 12, Line 8-9, and in Figures 3A and 6A, Dbp and Npas2 along with Clock expression are not affected in the liver of MAGED1 KO mice. However, we did not view this conflict with our model. As pointed out by Referee 2, although phenotypes between staggerer mice and Maged1 KO mice are comparable, the different Bmal1 levels between staggerer and Maged1 KO livers indicate that Maged1's effects on Bmal1 are not restricted to the interaction with RORα. We hypothesized that the Hox gene (described in the following paragraph) interaction protein MAGED1 may recruit other transcription factors to this regulatory module.
The idea of bidirectional effects by MAGED1 on circadian expression would be interesting
To further investigate how Maged1 may affect the circadian genes, we did in vivo ChIP using MAGED1 antibody. The methods were described in the Materials and Methods section on Page 25 Line 14-19. This experiment enables us to detect the promoter fragments associated with MAGED1 even though MAGED1 could not bind to the promoter directly. The results are consistent with the transcriptional level changes: Bmal1, Rev-erbα and E4bp4 promoter regions around the RORE sites were detected in MAGED1 precipitates, while promoter regions of the other three were not. We reasoned that although the promoters of Clock, Dbp and Npas2 genes harbor RORE sites, MAGED1 may be recruited to these regions with low affinity under physiological conditions, and have less effect than on the Bmal1, Rev-erbα and E4bp4 genes.
In addition, we compared the structure of all the RORE containing circadian gene promoters around the RORE sites using the rVista 2.0 program (Loots and Ovcharenko, 2004). Some conserved transcription factors such as Hox gene that might be MAGED1-binding proteins were predicted near the RORE sites at the promoters of Bmal1, Rev-erbα and E4bp4. In contrast, we did not find these sites in other RORE containing promoters during the same search. We agree that the data concerning the bidirectional regulation are very preliminary at this stage, but we do view this as an important hint, a hint for the existence of more unknown regulatory factors within the circadian gene promoters. These transcription binding sites near the RORE may regulate the binding strength of MAGED1 on ROR , functioning as a "module unit", and impose bidirectional functions on ROR . Thus, we added the following text to the discussion: "Interestingly, the reduction of Bmal1 mRNA level in the liver of Maged1 KO mice is more dramatic than that of staggerer mice (Ror mutant) or Ror KO mice. This discrepancy may reflect the redundant role of Ror proteins, whose adequate activations of Bmal1 all need Maged1. An alternative explanation is that other regulation factors may reside in the Bmal1 promoter to coordinate with ROR family by MAGED1. This is especially possible concerning the different responses of Bmal1, Rev-erbα and E4bp4 promoters to loss of Maged1. Furthermore, although a substantial set of circadian gene promoters harbour the functional RORE sequence, only Bmal1, Rev-erbα and E4bp4 show altered expression pattern in the liver of Maged1 KO mice, while others including Clock, Dbp and Npas2 are not affected. In parallel with this, only the promoter fragments of Bmal1, Rev-erbα and E4bp4 were found in Maged1 precipitates under our experimental conditions. Taken together, our data did show a preference of the RORE regulation by Maged1. The underlying mechanism suggests a model in which MAGED1 and unknown transcription factors binding on adjacent sites to the RORE lead to increased/decreased function of MAGED1 and RORα on divergent RORE promoters".
It is surprising that we see the difference of Maged1 mRNA expression between serum shock and dex treatment. Furthermore, it would be more interesting if we see circadian expression of Maged1 after serum shock. Take more time points in a circadian manner after serum shock and dex treatment and see the expression pattern and difference.
We are in complete agreement with the referee about adding time points to our investigation of the expression patterns and differences after serum shock and dexamethasone (dex) treatment. As suggested, we performed the circadian induction test after serum shock and dex treatment for 52 hr. 
In Figure 1 (C-F) the explanation of black (WT) and white (KO) bars is missing.
Thanks. We have added a definition of black and white bars on revised Page 26, Line 23. Figure 4C Gadph in the ordinate should be Gapdh.
In
We apologize for this mistake, which has now been rectified in the Figure 4C . Figure 7A the in situ images of SCN do not seem to show the center of SCN but its periphery.
Thanks. We have replaced Figure 7A .
5. On page 17 "epolepsia" should be "epilepsy".
Thanks. Revised. 
Two references (Bertrand

is barely an impact of the lack of ROR alpha on the rhythmic expression of the Bmal1 gene (Sato et al., 2004) in sharp contrast to the situation in the Maged1 KO mice. This is clearly a weak point of the manuscript. The action of MAGED1 on Bmal1 in the liver is clearly not restricted to the interaction with ROR alpha. Therefore, the entire argumentation regarding the importance of this interaction and the "direct"effects of MAGED1 on the circadian oscillator becomes quite soft and consequently the function of MAGED1 remains elusive. There should be more convincing experiments included to round up the story (e. g. chromatin immunoprecipitation of MAGED1 and ROR alpha at a target gene, co-immunoprecipitation of MAGED1 with other nuclear receptors involved in the regulation of the Bmal1, Rev-Erb alpha and E4BP4 genes in the liver, etc.)
The referee raised the concern on Maged1 regulation specificity. As he/she pointed out, we seemed to attribute the Maged1 co-activation role strictly to a ROR -dependent way. We would like to clarify this point by amending our original statement as well as the title. Since we failed to raise a working anti-ROR serum, we previously focused our statement on RORα for the in vivo coimmunoprecipitation. However, in our original manuscript, we did demonstrate that MAGED1 is able to augment the transcriptional activation role of both RORα and RORγ in HEK293 cells. Therefore, Maged1's co-regulation role is not restricted to RORα , and it is likely that RORα and RORγ may have a similar role in the regulation of liver Bmal1 expression. Considering the adequate activation of liver Bmal1 by RORα or RORγ both need Maged1, it is reasonable that due to the redundancy of RORα and RORγ , loss of Maged1 may lead to a more dramatic Bmal1 mRNA reduce than simply loss of RORα and RORγ . Accordingly, we noticed that a recent work has shown ROR could activate liver Bmal1 expression, while Bmal1 mRNA oscillation still retains fairly high amplitude in Rorγ -/-liver (Liu et al, 2008).
For the possible Maged1 co-regulation with other transcriptional factors, we have tested them in the luciferase assay (data not shown), and found no significant co-activation. We also performed coimmunoprecipitation between Maged1 and Rev-erb , and we found no direct interaction under our experimental conditions. For the rest ROR (Nr1f) member RORγ , we even did not observe an activation of Bmal1 by RORγ in HEK293 cells, which is consistent with the previous report that RORγ 's activation role is brain-specific (Greiner et al, 1996). However, we could not exclude the possibility that Maged1 may co-regulate with RORγ in SCN. Therefore, we are in complete agreement that our original title should be modified to avoid misleading. Thanks to the nice suggestion by the editor, we have adopted the title "Interaction of MAGED1 with nuclear receptors affects circadian clock function".
As suggested by the referee, we added ChIP results to reinforce our findings. We have amended our text on Page 13 Line 1 -7, and the results are in Figure 6F . The results support our conclusion that MAGED1 is directly associated with the RORE containing promoters of identified target genes. Together with our previous mutagenesis experiment in which Bmal1 promoter containing the mutant RORE sites fails to response to RORα and Maged1, we feel it is reasonable to conclude that the interaction between RORα and Maged1 is direct and important.
Finally, our in vivo ChIP assay did not detect all the RORE containing fragments from the circadian gene promoters. Only Bmal1, Rev-erb and E4bp4 promoters were detected, while promoters of Clock, Npas2 and Dbp were not. We view this as a hint for the existence of other transcription regulators, which may influence the preference of Maged1 regulation. We realize that showing recruitment of other transcriptional factors would be persuasive. As stated in our response to Referee 1, point 2, our supporting results are too preliminary for us to feel comfortable presenting results on this mechanism and it will be another interesting story. We have, however, raised this interesting point in the revised Discussion on Page 15 Line 23-24, Page 16 Line 1-14.
1) Introduction: The introduction (especially the first paragraph) is barely comprehensible for experts in the field let alone for a general readership. There should be clear definitions of "circadian clocks" and "circadian robustness". In addition, some references are not properly cited (page 4: Stokkan et al, 2001 was an important paper regarding the entrainment of peripheral oscillators by an inverted food regimen; the expression "sleep-wake", for which it was cited, shows up only once in the reference list.)
We thank the referee for these suggestions, and have rephrased the introduction page and corrected the citation errors. We thank the referee greatly for raising this point. We are in complete agreement with the referee that the paper would be enhanced by clarifying whether the effect of Maged1-ROR on the Rev-erb promoter is direct or indirect. The Rev-erbα promoter we used in our luciferase assay was a kind gift from Laure Bernard and Vincent Laudet (Adelmant, et al, PNAS, 1996) , who have characterized a functional RRE element (Rp, the proximal RORE) near the transcriptional start site that is conserved between humans and mice; and Delerive et al have characterized another RORE (Rd, the distal RORE) within the same promoter (Delerive, et al, JBC, 2002). We apologize for the missing references of the promoter used, and we have incorporated these references into the revised manuscript Page 12 line 14.
2) Citation of the reference should be better in accordance with
We also highly appreciate the alternative explanation presented by the referee for the increase of Rev-erb expression. To clarify this point, we reason that if Rev-erb 's up-regulation is due to the significant down-regulation of its repressor E4bp4, then other D-box containing genes will likely exhibit a similar response, since the function of a transcription repressor is more straightforward than that of a co-regulator. However, when we examined this in our data for the transcriptional level changes, we did not find up-regulation of other D-box containing genes (Per1, Per2 and Rev-erb ). Thus, we feel that the decrease of E4bp4 may partially but not completely contribute to the increase of Rev-erbα expression. In addition, in the luciferase assay, we found that addition of Maged1 brings down the activation by RORα . Finally, as recommended by Referee 2, we have added ChIP data that demonstrate a direct association of Maged1 in the native chromatin of Rev-erbα locus. The result is shown in Figure 6F and described on Page 13 Line 1-7.
2. In Fig.2 We understand the dissatisfaction expressed by the referee, and hoped to include the suggested experiments. We made every effort to observe liver and SCN oscillator curves, but they were dampened within two cycles, even at the recommended temperature and with culture plate inserts As suggested, we have added liver data in Figure 3D . The phosphorylated form of Bmal1 is hard to discern in both wild type and knockout liver tissues. Fig.5C We apologize for the confusion caused by using Maged1-/-for male KO mice. We have replaced Maged1 -/-/mPER2::LUC MEF cells with "Maged1 KO/mPER2::LUC MEF cells in revised manuscript (Page 8 Line 7-8 ). We did cross Maged1+/-female to the mPER2::LUC homo knock-in reporter male mice and got Maged1 KO and wild type MEFs. We have clarified this issue in revised manuscript "by crossing Maged1+/-female mice to the homozygous mPER2::LUC knock-in reporter male mice" on Page 7 Line 21-22. We thank the referee for the very nice suggestion concerning the female mice. For the male mice, since Maged1 is located in Chromosome X, no heterozygous males exist, so we examined the phenotype of +/Y and -/Y mice as we previously stated. All the subjects we used in the experiments were generated from Strategy 1 as listed in the following table.
In
At page12, they mentioned that they used "3T3 NIH cells" (line6) and "NIH3T3 cells" (line13
For the female mice, the only way to generate the Maged1-/-homozygous mice along with control littermates is illustrated in Strategy 2 of the table. The consequence is that no wild-type female littermates exist. In addition, this strategy is relatively difficult to implement due to the possible reproductive defects of Maged1 KO mice. However, as the referee recommended, we included these data in Figure S2 of the revised manuscript. The corresponding description is on Page 6 Line 2-5. The difference between Maged1 KO homozygous and heterozygous females exists but does not have statistical significance, possibly due to the large variation for Maged1-/-female mice. As a complement, we also examined the Maged1+/+ and -/+ female mice generated from Strategy 1 to see if loss of one copy of Maged1 is already sufficient to affect the circadian behavior. As illustrated in Figure S2 , female mice lacking Maged1 do exhibit a shortened circadian period in a Maged1 copy number-dependent manner. Therefore, we conclude that the phenotype we observed is not genderspecific; rather, it is Maged1 dependent. To avoid confusion, we have added the mating strategies as Table S1 in revised manuscript. (Fig.3A) . Ideally speaking, the authors should observe at least two cycles of genes expression for confirmation.
As recommended, we collected two cycles of samples and did Q-PCR. Now the Fig. 3A has been replaced with the new one.
2nd Editorial Decision 17 February 2010
Thank you for submitting your revised manuscript. It has now been seen once more by the original referees 1 and 2. I am happy to inform you that both of them consider the manuscript now in principle suitable for publication in The EMBO Journal. Nevertheless, referee 1 indicates a few minor mistakes that should be corrected, and referee 2 remains somewhat unhappy about the overall -editorial -quality of the manuscript. I am therefore returning the study to you once more, kindly asking you to incorporate these additional changes and to carefully edit and proofread the manuscript in this last round of revision. Once we will have received this final version, I hope we should then be able to proceed with the acceptance of your paper.
I am looking forward to receiving your final version.
Yours sincerely,
Editor
The EMBO Journal _____ Thank you very much for your reply. We are happy that you and the reviewers gave us the opportunity. I do apologize for the mistakes and have corrected all these errors. Unified Figure 7F CT 4, 10 *** were added
We thank you again for your efforts.
Additional correspondence 19 February 2010
Many thanks for submitting the revised version of your manuscript. Having looked through your final revision, I am pleased to be able to tell you that we can now accept your manuscript for publication -you should receive the formal acceptance message shortly.
Also, I would like to pass on to you the comments of Referee 3 on your previous revision -we only received these yesterday, after we had written to you with our decision. As you will see, this referee is supportive of publication, although he/she does make additional suggestions. Obviously, we do not think it necessary for you to address these points, but I wanted you to have the comments for your information.
